These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7399353)

  • 21. Human fibrinogen and asialo-fibrinogen: a comparison of coagulation parameters.
    Gentry PA; Alexander B
    Arch Biochem Biophys; 1976 Mar; 173(1):50-7. PubMed ID: 176955
    [No Abstract]   [Full Text] [Related]  

  • 22. Congenital afibrinogenemia diagnosis by estimating plasma fibrinogen by conventional method with clinical correlation.
    Goswami K; Nandakumar DN; Soundravally R; Nandeesha H; Das V; Kannan R; Nalini P; Koner BC
    Indian J Pathol Microbiol; 2008; 51(2):310-1. PubMed ID: 18603723
    [No Abstract]   [Full Text] [Related]  

  • 23. Potential misdiagnosis of dysfibrinogenaemia: Data from multicentre studies amongst UK NEQAS and PRO-RBDD project laboratories.
    Jennings I; Kitchen S; Menegatti M; Palla R; Walker I; Peyvandi F; Makris M
    Int J Lab Hematol; 2017 Dec; 39(6):653-662. PubMed ID: 28766854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrinogen Milano V: a congenital dysfibrinogenaemia with a gamma 275 Arg-->Cys substitution.
    Steinmann C; Bögli C; Jungo M; Lämmle B; Heinemann G; Wermuth B; Redaelli R; Baudo F; Furlan M
    Blood Coagul Fibrinolysis; 1994 Aug; 5(4):463-71. PubMed ID: 7841300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Congenital and familial dysfibrinogenemia without hemorrhagic tendancy].
    Samama M; Soria J; Soria C; Bousser J
    Nouv Rev Fr Hematol; 1969; 9(6):817-32. PubMed ID: 4245042
    [No Abstract]   [Full Text] [Related]  

  • 26. Episodes of increased fibronectin level observed in a patient suffering from recurrent thrombosis related to congenital hypodysfibrinogenaemia (fibrinogen Malmoe).
    Soria J; Soria C; Hedner U; Nilsson IM; Bergqvist D; Samama M
    Br J Haematol; 1985 Dec; 61(4):727-38. PubMed ID: 4084461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Diagnostic studies in congenital afibrinogenemia].
    Gadner H; Barthels M; Petersen N; Riehm H
    Monatsschr Kinderheilkd (1902); 1974 Jul; 122(7):691-3. PubMed ID: 4409212
    [No Abstract]   [Full Text] [Related]  

  • 28. [Hypodysfibrinogenemia: fibrinogen giessen II (author's transl)].
    Krause WH; Huth K; Heene DL; Lasch HG
    Klin Wochenschr; 1975 Aug; 53(16):781-2. PubMed ID: 1165625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibrinogen Milano IV, another case of congenital dysfibrinogenemia with an abnormal fibrinopeptide A release (A alpha 16 Arg----His).
    Bögli C; Hofer A; Baudo F; Redaelli R; Furlan M
    Haemostasis; 1992; 22(1):7-11. PubMed ID: 1521828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening of dysfibrinogenaemia using the fibrinogen function versus antigen concentration ratio.
    Krammer B; Anders O; Nagel HR; Burstein C; Steiner M
    Thromb Res; 1994 Dec; 76(6):577-9. PubMed ID: 7900105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting.
    Greenberg CS; Miraglia CC; Rickles FR; Shuman MA
    J Clin Invest; 1985 May; 75(5):1463-70. PubMed ID: 2860124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the factors contributing to fibrin-dependent plasminogen activation.
    Mosesson MW; Siebenlist KR; Voskuilen M; Nieuwenhuizen W
    Thromb Haemost; 1998 Apr; 79(4):796-801. PubMed ID: 9569195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. "Fibrinogen Tokyo II". An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules.
    Matsuda M; Baba M; Morimoto K; Nakamikawa C
    J Clin Invest; 1983 Sep; 72(3):1034-41. PubMed ID: 6886002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An abnormal fibrinogen (Copenhagen II) with increased sialic acid content associated with thrombotic tendency and normal liver function.
    Hansen MS; Schousboe I
    Scand J Haematol; 1984 Jul; 33(1):9-14. PubMed ID: 6205441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Congenital dysfibrinogenemia.
    Rupp C; Beck EA
    Curr Probl Clin Biochem; 1984; 14():65-130. PubMed ID: 6150812
    [No Abstract]   [Full Text] [Related]  

  • 36. Dysfibrinogenemia associated with hepatoma. Increased carbohydrate content of the fibrinogen molecule.
    Gralnick HR; Givelber H; Abrams E
    N Engl J Med; 1978 Aug; 299(5):221-6. PubMed ID: 207986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of sodium citrate in the dysfibrinogenaemia of liver disease.
    Francis JL; Watson NJ; Simmonds VJ
    Thromb Res; 1984 May; 34(3):187-97. PubMed ID: 6729777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel fibrinogen variant--Liberec: dysfibrinogenaemia associated with gamma Tyr262Cys substitution.
    Kotlín R; Sobotková A; Suttnar J; Salaj P; Walterová L; Riedel T; Reicheltová Z; Dyr JE
    Eur J Haematol; 2008 Aug; 81(2):123-9. PubMed ID: 18485115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibrinogen Bethesda: a congenital dysfibrinogenemia with delayed fibrinopeptide release.
    Gralnick HR; Givelber HM; Shainoff JR; Finlayson JS
    J Clin Invest; 1971 Sep; 50(9):1819-30. PubMed ID: 5564389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies on a family with dysfibrinogenemia.
    Mammen EF; Prasad AS; Au CC
    Thromb Diath Haemorrh; 1968 Jul; 19(3):03-4. PubMed ID: 5708123
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.